6533b825fe1ef96bd12827d9

RESEARCH PRODUCT

Epidermal growth factor receptor in human breast cancer: Correlation with cytosolic and nuclear ER receptors and with biological and histological tumor characteristics

Carlos VazquezFrancisco MirallesTeresa OlmosAntonio Luis Terrones RodríguezJavier García-condeAna LluchPascual Bolufer

subject

Adultmedicine.medical_specialtyBreast NeoplasmsReceptors EstradiolCorrelationCytosolEpidermal growth factorInternal medicinemedicineHumansEpidermal growth factor receptorReceptorAgedAged 80 and overCell NucleusbiologyCancerMiddle Agedmedicine.diseasePathophysiologyErbB ReceptorsCytosolCarcinoma Intraductal NoninfiltratingEndocrinologyOncologybiology.proteinHuman breast

description

Epidermal growth factor receptor (EGFr) and cytosolic (cER) and nuclear (nER) estradiol receptors were quantified in 220 primary breast cancers. The EGFr was significantly more frequent (chi 2 = 5.9; P less than 0.025) and its concentration was significantly higher (P less than 0.001) among ER- tumors than in ER+ tumors. There was a significantly greater proportion (chi 2 = 6.4; P less than 0.05) of node involvement in EGFr+/ER+ tumors than in EFGr-/ER+. Increases in the proportion of EGFr+ in ER- tumors are parallel to Scarff-Bloom scores (chi 2 = 6.1; P less than 0.05) and there is a significant trend (Spearman rs = 0.25; P less than 0.05) towards increased EGFr concentrations with histologic dedifferentiation. In ER+ tumors the median concentrations of EGFr in the different age groups show a linear correlation (LCC = 0.89; P less than 0.05) and follow a parallel profile with the medians of nER. These findings support the hypothesis that EGFr is a bad prognosis factor and suggest that EGFr expression and concentration in ER+ tumors might be considered an estrogenic action mediated through the binding of ER to their nuclear acceptors.

yearjournalcountryeditionlanguage
1990-03-01European Journal of Cancer and Clinical Oncology
https://doi.org/10.1016/0277-5379(90)90223-g